← 治験一覧に戻る
未治療の局所進行性または転移性尿路上皮癌におけるエンフォルツマブ・ベドチンとペムブロリズマブの併用と化学療法単独の比較
基本情報
- NCT ID
- NCT04223856
- ステータス
- 実施中（募集終了）
- 試験のフェーズ
- 第3相
- 試験タイプ
- 介入
- 目標被験者数
- 886
- 治験依頼者名
- Astellas Pharma Inc
概要
This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together to treat patients with urothelial cancer. The study will compare these drugs to other drugs that are usually used to treat this cancer (standard of care). The patients in this study will have cancer that has spread from their urinary system to other parts of their body.
対象疾患
Urothelial Cancer
介入
Enfortumab vedotin(DRUG)
Pembrolizumab(DRUG)
Cisplatin(DRUG)
Carboplatin(DRUG)
Gemcitabine(DRUG)